160
Participants
Start Date
October 25, 2022
Primary Completion Date
May 23, 2023
Study Completion Date
January 4, 2024
Placebo
Subjects will receive several injections of Placebo
HB0017
Subjects will receive HB0017 in different dosing regimens
The First Affiliated Hospital of Bengbu Medical College, Bengbu
The First Affiliated Hospital of Anhui Medical University, Hefei
The Second Hospital of Anhui Medical University, Hefei
The First Affiliated Hospital of Wannan Medical College, Wuhu
Dermatology Hospital of Southern Medical University, Guangzhou
Guangdong Provincial People's Hospital, Guangzhou
The first hospital of Hebei Medical University, Shijiazhuang
The Second Xiangya Hospital of Central South University, Changsha
The Third Xiangya Hospital of Central South University, Changsha
Xiangya Hospital of Central South University, Changsha
Affiliated Hospital of Jiangsu University, Zhenjiang
Dermatology Hospital of Jiangxi Province, Nanchang
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan
Skin Disease Hospital of Shandong First Medical University, Jinan
Yantai Yuhuangding hospital, Yantai
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
The Third People's Hospital of Hangzhou, Hangzhou
Peking University People's Hospital, Beijing
Peking University Third Hospital, Beijing
Shanghai Skin Disease Hospital, Shanghai
Lead Sponsor
Huabo Biopharm Co., Ltd.
INDUSTRY